Treace Medical (TMCI) Q2 2026 earnings review
Mix-Shift Headwinds Ease as Strategic Pivot Takes Hold
Treace Medical is successfully navigating its painful transition to a comprehensive bunion solutions company. While Q2 revenue declined 4% YoY to $45.4 million, this represents a meaningful sequential deceleration in the rate of decline compared to Q1's 10% drop. The core strategy—trading near-term average selling price (ASP) for market share—is working operationally: surgeon adoption of new, lower-priced minimally invasive (MIS) systems hit 40%. Crucially, the top-line pressure is being offset by ruthless cost control. Operating expenses fell 8%, keeping the Adjusted EBITDA loss stable at $3.5 million and reducing YTD cash usage by 57%. Management raised the low end of their revenue guidance and improved EBITDA outlook, signaling confidence that the worst of the mix-shift headwind is in the rearview mirror.
🐂 Bull Case
Approximately 40% of the Lapiplasty surgeon base is now using one or more of the new bunion systems, up sequentially from 35% in Q1 and 25% in 25Q4. The strategy to capture the 70% osteotomy market is yielding results.
An 8% reduction in operating expenses drove a massive 57% YoY reduction in cash usage for the first half of the year, de-risking the balance sheet while the top line recovers.
🐻 Bear Case
Despite sequential improvement, the company is still reporting negative YoY revenue growth (-4%) due to the severe ASP headwind from lower-priced MIS products.
Gross margin compressed to 78.5% from 79.7% a year ago. As the product mix continues to shift toward MIS, structural gross margin degradation remains a risk.
⚖️ Verdict: ⚪
Neutral. The operational metrics (adoption, cost control) are highly encouraging, but the company must prove it can return to absolute revenue growth in the second half of the year as guided.
Key Themes
Surgeon Penetration is Accelerating
The core driver of the company's turnaround is the adoption of its new MIS systems (Nanoplasty, Percuplasty, SpeedMTP). Penetration within the existing Lapiplasty user base accelerated to 40% in Q2, up from 35% in Q1 and 25% in Q4 of 2025. This confirms that the expanded portfolio is successfully capturing procedure volumes that were previously leaking to competitors.
Ruthless Expense Control
Treace is proving it can manage profitability while shrinking the top line. Total operating expenses decreased 8% YoY to $50.6 million. This targeted expense reduction initiative cut YTD cash usage by 57% (saving $3.6 million). By right-sizing the cost structure, management has bought the company ample runway to weather the revenue mix-shift transition.
Portfolio Expansion into Adjacencies
The company initiated the limited market release of the SuperBite Compression Screw System and completed the first case with the HyperPlate XM Dynamic Compression Locking Implant System. These specific product innovations are critical drivers for the second half, opening up an estimated $300 million in incremental TAM by targeting midfoot and hindfoot procedures.
ASP Headwinds Masking Volume Growth
A direct contradiction to the positive narrative around case volume growth is the negative revenue print. Case volumes are rising, but because surgeons are adopting lower-priced MIS products instead of the premium Lapiplasty system, total revenue fell 4%. This negative mix shift will continue to cap revenue growth until the company fully laps the product launches.
Gross Margin Compression
Gross margin decelerated to 78.5% in Q2, down from 79.7% in the prior year period. While still robust, this compression highlights the profitability penalty of shifting heavily into the MIS osteotomy segment. The floor for these margins must be closely monitored.
H2 Execution and Macro Risks
The updated FY26 guidance heavily relies on returning to revenue growth in the second half of the year. This requires flawless execution of new product rollouts and assumes a normalization of the macroeconomic pressures and soft consumer sentiment that disrupted elective surgery demand in prior quarters.
Other KPIs
Stable YoY compared to $(3.6) million in 25Q2. The company completely offset the $2.0 million decline in gross profit with $4.1 million in operating expense reductions, demonstrating highly responsive cost management.
Comprised of $45.6 million in cash, cash equivalents, and marketable securities, plus $115 million available on the credit facility. Given the 57% reduction in YTD cash burn, liquidity risks are effectively off the table for the near term.
Guidance
Accelerating. The company raised the low end of its prior guidance ($202 - $212 million). The new range implies a full-year decline of 4% to 0%. Because H1 revenue declined 7% on average, hitting this guidance mathematically requires a return to near-flat or positive growth in the second half of the year.
Accelerating. The outlook was significantly improved from the prior expectation of a $4.0 - $6.0 million loss. This indicates that the Q2 OpEx reductions were not a one-time event, but part of a structural cost realignment that will benefit the full year.
Stable. The company reiterated its expectation to halve its cash burn compared to FY25. With a 57% reduction already achieved in H1, they are tracking well ahead of this goal.
Key Questions
Lapiplasty Pull-Through
With 40% of the base now using the new MIS systems, what specific metrics can you share regarding the 'pull-through' effect? Are these new MIS users actively transitioning their complex cases back to Lapiplasty as originally hypothesized?
Gross Margin Floor
Gross margin dipped to 78.5% due to the product mix shift. As MIS adoption continues to grow as a percentage of total volume, where do you view the structural floor for gross margins over the next 12-18 months?
H2 Macro Assumptions
Your guidance implies a return to growth in the second half. To what extent does this rely on an improvement in the consumer sentiment and elective procedure macro environment versus purely internal new product execution?